Do analysts prefer MGRX or GXAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Gaxos.ai 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is MGRX or GXAI more profitable?

Gaxos.ai has a net margin of -64.81% compared to Mangoceuticals' net margin of -4,794.60%. Gaxos.ai's return on equity of -38.79% beat Mangoceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Mangoceuticals -4,794.60% -96.39% -89.60% Gaxos.ai -64.81% -38.79% -36.99%

Does the media refer more to MGRX or GXAI?

In the previous week, Gaxos.ai had 1 more articles in the media than Mangoceuticals. MarketBeat recorded 3 mentions for Gaxos.ai and 2 mentions for Mangoceuticals. Mangoceuticals' average media sentiment score of 0.00 beat Gaxos.ai's score of -0.36 indicating that Mangoceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mangoceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Gaxos.ai 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer GXAI or BMGL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gaxos.ai 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Basel Medical Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, GXAI or BMGL?

Gaxos.ai has higher earnings, but lower revenue than Basel Medical Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gaxos.ai $1.93M 3.32 -$3.90M -$0.50 N/A Basel Medical Group $8.90M 0.67 -$9.50M N/A N/A

Do analysts recommend GXAI or AIDX?

20/20 Biolabs has a consensus target price of $5.00, indicating a potential upside of 1,081.75%. Given 20/20 Biolabs' stronger consensus rating and higher possible upside, analysts clearly believe 20/20 Biolabs is more favorable than Gaxos.ai. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gaxos.ai 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 20/20 Biolabs 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is GXAI or AIDX more profitable?

20/20 Biolabs has a net margin of 0.00% compared to Gaxos.ai's net margin of -64.81%. 20/20 Biolabs' return on equity of 0.00% beat Gaxos.ai's return on equity. Company Net Margins Return on Equity Return on Assets Gaxos.ai -64.81% -38.79% -36.99% 20/20 Biolabs N/A N/A N/A

Does the media favor GXAI or AIDX?

In the previous week, Gaxos.ai and Gaxos.ai both had 3 articles in the media. 20/20 Biolabs' average media sentiment score of 0.00 beat Gaxos.ai's score of -0.36 indicating that 20/20 Biolabs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gaxos.ai 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral 20/20 Biolabs 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer BIAF or GXAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score bioAffinity Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Gaxos.ai 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer BIAF or GXAI?

In the previous week, bioAffinity Technologies and bioAffinity Technologies both had 3 articles in the media. bioAffinity Technologies' average media sentiment score of 0.38 beat Gaxos.ai's score of -0.36 indicating that bioAffinity Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment bioAffinity Technologies 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Gaxos.ai 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend IVF or GXAI?

INVO Fertility presently has a consensus target price of $20.00, suggesting a potential upside of 2,022.47%. Given INVO Fertility's stronger consensus rating and higher possible upside, research analysts plainly believe INVO Fertility is more favorable than Gaxos.ai. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INVO Fertility 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Gaxos.ai 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is IVF or GXAI more profitable?

Gaxos.ai has a net margin of -64.81% compared to INVO Fertility's net margin of -116.29%. Gaxos.ai's return on equity of -38.79% beat INVO Fertility's return on equity. Company Net Margins Return on Equity Return on Assets INVO Fertility -116.29% -85.54% -31.05% Gaxos.ai -64.81% -38.79% -36.99%

Does the media prefer IVF or GXAI?

In the previous week, INVO Fertility had 1 more articles in the media than Gaxos.ai. MarketBeat recorded 4 mentions for INVO Fertility and 3 mentions for Gaxos.ai. INVO Fertility's average media sentiment score of 0.76 beat Gaxos.ai's score of -0.36 indicating that INVO Fertility is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment INVO Fertility 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Gaxos.ai 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Gaxos.ai (GXAI) Competitors

$0.60 +0.02 (+2.81%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$0.62 +0.02 (+2.95%)

As of 09/24/2026 07:54 PM Eastern

Compare

GXAI vs. MGRX, BMGL, AIDX, BIAF, and IVF

Should you buy Gaxos.ai stock or one of its competitors? Gaxos.ai's main competitors and comparable companies include Mangoceuticals (MGRX), Basel Medical Group (BMGL), 20/20 Biolabs (AIDX), bioAffinity Technologies (BIAF), and INVO Fertility (IVF). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Gaxos.ai compare to Mangoceuticals?

Mangoceuticals (NASDAQ:MGRX) and Gaxos.ai (NASDAQ:GXAI) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

Mangoceuticals has a beta of 2.04, indicating that its share price is 104% more volatile than the broader market. Comparatively, Gaxos.ai has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market.

In the previous week, Gaxos.ai had 1 more articles in the media than Mangoceuticals. MarketBeat recorded 3 mentions for Gaxos.ai and 2 mentions for Mangoceuticals. Mangoceuticals' average media sentiment score of 0.00 beat Gaxos.ai's score of -0.36 indicating that Mangoceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mangoceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Gaxos.ai	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Gaxos.ai has higher revenue and earnings than Mangoceuticals. Gaxos.ai is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mangoceuticals	$460K	21.76	-$20.64M	-$1.01	N/A
Gaxos.ai	$1.93M	3.32	-$3.90M	-$0.50	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Gaxos.ai	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

56.7% of Mangoceuticals shares are held by institutional investors. Comparatively, 42.6% of Gaxos.ai shares are held by institutional investors. 16.0% of Mangoceuticals shares are held by insiders. Comparatively, 3.2% of Gaxos.ai shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Gaxos.ai has a net margin of -64.81% compared to Mangoceuticals' net margin of -4,794.60%. Gaxos.ai's return on equity of -38.79% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mangoceuticals	-4,794.60%	-96.39%	-89.60%
Gaxos.ai	-64.81%	-38.79%	-36.99%

Summary

Gaxos.ai beats Mangoceuticals on 7 of the 13 factors compared between the two stocks.

How does Gaxos.ai compare to Basel Medical Group?

Gaxos.ai (NASDAQ:GXAI) and Basel Medical Group (NASDAQ:BMGL) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, earnings, risk and valuation.

Gaxos.ai has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market. Comparatively, Basel Medical Group has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market.

Gaxos.ai has higher earnings, but lower revenue than Basel Medical Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gaxos.ai	$1.93M	3.32	-$3.90M	-$0.50	N/A
Basel Medical Group	$8.90M	0.67	-$9.50M	N/A	N/A

Basel Medical Group has a net margin of 0.00% compared to Gaxos.ai's net margin of -64.81%. Basel Medical Group's return on equity of 0.00% beat Gaxos.ai's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gaxos.ai	-64.81%	-38.79%	-36.99%
Basel Medical Group	N/A	N/A	N/A

42.6% of Gaxos.ai shares are owned by institutional investors. 3.2% of Gaxos.ai shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Gaxos.ai had 1 more articles in the media than Basel Medical Group. MarketBeat recorded 3 mentions for Gaxos.ai and 2 mentions for Basel Medical Group. Basel Medical Group's average media sentiment score of 0.00 beat Gaxos.ai's score of -0.36 indicating that Basel Medical Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Gaxos.ai	Neutral
Basel Medical Group	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gaxos.ai	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Basel Medical Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Gaxos.ai beats Basel Medical Group on 6 of the 11 factors compared between the two stocks.

How does Gaxos.ai compare to 20/20 Biolabs?

Gaxos.ai (NASDAQ:GXAI) and 20/20 Biolabs (NASDAQ:AIDX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

42.6% of Gaxos.ai shares are owned by institutional investors. 3.2% of Gaxos.ai shares are owned by company insiders. Comparatively, 29.8% of 20/20 Biolabs shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

20/20 Biolabs has a net margin of 0.00% compared to Gaxos.ai's net margin of -64.81%. 20/20 Biolabs' return on equity of 0.00% beat Gaxos.ai's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gaxos.ai	-64.81%	-38.79%	-36.99%
20/20 Biolabs	N/A	N/A	N/A

In the previous week, Gaxos.ai and Gaxos.ai both had 3 articles in the media. 20/20 Biolabs' average media sentiment score of 0.00 beat Gaxos.ai's score of -0.36 indicating that 20/20 Biolabs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gaxos.ai	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
20/20 Biolabs	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

20/20 Biolabs has a consensus target price of $5.00, indicating a potential upside of 1,081.75%. Given 20/20 Biolabs' stronger consensus rating and higher possible upside, analysts clearly believe 20/20 Biolabs is more favorable than Gaxos.ai.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gaxos.ai	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
20/20 Biolabs	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

20/20 Biolabs has higher revenue and earnings than Gaxos.ai. Gaxos.ai is trading at a lower price-to-earnings ratio than 20/20 Biolabs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gaxos.ai	$1.93M	3.32	-$3.90M	-$0.50	N/A
20/20 Biolabs	$2.05M	2.64	-$3.74M	-$0.54	N/A

Summary

20/20 Biolabs beats Gaxos.ai on 11 of the 14 factors compared between the two stocks.

How does Gaxos.ai compare to bioAffinity Technologies?

bioAffinity Technologies (NASDAQ:BIAF) and Gaxos.ai (NASDAQ:GXAI) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk, media sentiment and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
bioAffinity Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Gaxos.ai	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

1.6% of bioAffinity Technologies shares are held by institutional investors. Comparatively, 42.6% of Gaxos.ai shares are held by institutional investors. 2.7% of bioAffinity Technologies shares are held by insiders. Comparatively, 3.2% of Gaxos.ai shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

bioAffinity Technologies has a beta of -1.11, meaning that its share price is 211% less volatile than the broader market. Comparatively, Gaxos.ai has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market.

Gaxos.ai has a net margin of -64.81% compared to bioAffinity Technologies' net margin of -257.30%. Gaxos.ai's return on equity of -38.79% beat bioAffinity Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
bioAffinity Technologies	-257.30%	-220.52%	-136.76%
Gaxos.ai	-64.81%	-38.79%	-36.99%

In the previous week, bioAffinity Technologies and bioAffinity Technologies both had 3 articles in the media. bioAffinity Technologies' average media sentiment score of 0.38 beat Gaxos.ai's score of -0.36 indicating that bioAffinity Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
bioAffinity Technologies	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Gaxos.ai	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Gaxos.ai has lower revenue, but higher earnings than bioAffinity Technologies. Gaxos.ai is trading at a lower price-to-earnings ratio than bioAffinity Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
bioAffinity Technologies	$6.16M	0.76	-$14.91M	-$109.45	N/A
Gaxos.ai	$1.93M	3.32	-$3.90M	-$0.50	N/A

Summary

Gaxos.ai beats bioAffinity Technologies on 9 of the 12 factors compared between the two stocks.

How does Gaxos.ai compare to INVO Fertility?

INVO Fertility (NASDAQ:IVF) and Gaxos.ai (NASDAQ:GXAI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations and earnings.

Gaxos.ai has a net margin of -64.81% compared to INVO Fertility's net margin of -116.29%. Gaxos.ai's return on equity of -38.79% beat INVO Fertility's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INVO Fertility	-116.29%	-85.54%	-31.05%
Gaxos.ai	-64.81%	-38.79%	-36.99%

INVO Fertility has a beta of 2.34, indicating that its stock price is 134% more volatile than the broader market. Comparatively, Gaxos.ai has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market.

12.0% of INVO Fertility shares are owned by institutional investors. Comparatively, 42.6% of Gaxos.ai shares are owned by institutional investors. 0.4% of INVO Fertility shares are owned by company insiders. Comparatively, 3.2% of Gaxos.ai shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

INVO Fertility presently has a consensus target price of $20.00, suggesting a potential upside of 2,022.47%. Given INVO Fertility's stronger consensus rating and higher possible upside, research analysts plainly believe INVO Fertility is more favorable than Gaxos.ai.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INVO Fertility	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Gaxos.ai	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Gaxos.ai has lower revenue, but higher earnings than INVO Fertility. Gaxos.ai is trading at a lower price-to-earnings ratio than INVO Fertility, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INVO Fertility	$6.84M	0.35	-$25.13M	-$33.83	N/A
Gaxos.ai	$1.93M	3.32	-$3.90M	-$0.50	N/A

In the previous week, INVO Fertility had 1 more articles in the media than Gaxos.ai. MarketBeat recorded 4 mentions for INVO Fertility and 3 mentions for Gaxos.ai. INVO Fertility's average media sentiment score of 0.76 beat Gaxos.ai's score of -0.36 indicating that INVO Fertility is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
INVO Fertility	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Gaxos.ai	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

INVO Fertility beats Gaxos.ai on 9 of the 16 factors compared between the two stocks.

Get Gaxos.ai News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GXAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GXAI vs. The Competition

Export

Metric	Gaxos.ai	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.23M	$9.74B	$7.32B	$13.29B
Dividend Yield	N/A	2.59%	2.52%	12.57%
P/E Ratio	-1.19	34.16	274.40	25.76
Price / Sales	3.32	4.96	688.47	106.32
Price / Cash	N/A	122.11	77.80	52.76
Price / Book	0.33	5.19	10.52	6.34
Net Income	-$3.90M	$315.70M	$3.49B	$360.00M
7 Day Performance	-0.48%	-1.37%	-0.94%	-0.16%
1 Month Performance	-26.73%	-1.39%	-4.24%	-4.07%
1 Year Performance	-65.67%	13.93%	16.39%	5.97%

Gaxos.ai Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GXAI Gaxos.ai	0.5223 of 5 stars	$0.60 +2.8%	N/A	-67.9%	$6.23M	$1.93M	N/A	3	High Trading Volume
MGRX Mangoceuticals	0.8241 of 5 stars	$0.45 +4.1%	N/A	-80.9%	$9.68M	$460K	N/A	3
BMGL Basel Medical Group	0.0771 of 5 stars	$4.09 -2.4%	N/A	-82.5%	$6.46M	$8.90M	N/A	70	Short Interest Increase
AIDX 20/20 Biolabs	2.0642 of 5 stars	$0.43 -9.3%	$5.00 +1,072.1%	N/A	$5.45M	$2.05M	N/A	14	Short Interest Decrease
BIAF bioAffinity Technologies	0.4397 of 5 stars	$7.94 -7.2%	N/A	-87.8%	$4.76M	$6.16M	N/A	57	Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GXAI) was last updated on 9/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gaxos.ai (GXAI) Competitors

GXAI vs. MGRX, BMGL, AIDX, BIAF, and IVF

How does Gaxos.ai compare to Mangoceuticals?

Summary

How does Gaxos.ai compare to Basel Medical Group?

Summary

How does Gaxos.ai compare to 20/20 Biolabs?

Summary

How does Gaxos.ai compare to bioAffinity Technologies?

Summary

How does Gaxos.ai compare to INVO Fertility?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GXAI vs. The Competition

Gaxos.ai Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gaxos.ai (GXAI) Competitors

GXAI vs. MGRX, BMGL, AIDX, BIAF, and IVF

How does Gaxos.ai compare to Mangoceuticals?

Which has more volatility & risk, MGRX or GXAI?

Does the media refer more to MGRX or GXAI?

Which has higher valuation & earnings, MGRX or GXAI?

Do analysts prefer MGRX or GXAI?

Do institutionals and insiders have more ownership in MGRX or GXAI?

Is MGRX or GXAI more profitable?

Summary

How does Gaxos.ai compare to Basel Medical Group?

Which has more volatility & risk, GXAI or BMGL?

Which has stronger earnings & valuation, GXAI or BMGL?

Is GXAI or BMGL more profitable?

Do institutionals and insiders believe in GXAI or BMGL?

Does the media prefer GXAI or BMGL?

Do analysts prefer GXAI or BMGL?

Summary

How does Gaxos.ai compare to 20/20 Biolabs?

Do institutionals & insiders have more ownership in GXAI or AIDX?

Is GXAI or AIDX more profitable?

Does the media favor GXAI or AIDX?

Do analysts recommend GXAI or AIDX?

Which has preferable earnings & valuation, GXAI or AIDX?

Summary

How does Gaxos.ai compare to bioAffinity Technologies?

Do analysts prefer BIAF or GXAI?

Do insiders & institutionals have more ownership in BIAF or GXAI?

Which has more volatility & risk, BIAF or GXAI?

Is BIAF or GXAI more profitable?

Does the media prefer BIAF or GXAI?

Which has stronger earnings and valuation, BIAF or GXAI?

Summary

How does Gaxos.ai compare to INVO Fertility?

Is IVF or GXAI more profitable?

Which has more volatility & risk, IVF or GXAI?

Do insiders & institutionals hold more shares of IVF or GXAI?

Do analysts recommend IVF or GXAI?

Which has stronger valuation and earnings, IVF or GXAI?

Does the media prefer IVF or GXAI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GXAI vs. The Competition

Gaxos.ai Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools